Literature DB >> 1828167

Viridans streptococcal bacteraemia in patients with haematological and solid malignancies.

A D Burden1, B A Oppenheim, D Crowther, A Howell, G R Morgenstern, J H Scarffe, N Thatcher.   

Abstract

Thirty-three episodes of septicaemia caused by viridans streptococci are reported in 32 adults under treatment for malignant diseases. The underlying diseases were acute leukaemia (17), lymphoma (4), myeloma (1), small cell carcinoma of the bronchus (6), carcinoma of the breast (2) and carcinoma of the stomach (2). Important predisposing factors included severe neutropenia and oral mucositis due to intensive chemotherapeutic regimens. There was a poor response to standard empirical antibiotics and a mortality of 12%. A role for prophylactic penicillin in high risk groups is suggested.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1828167     DOI: 10.1016/0277-5379(91)90373-l

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  11 in total

1.  Lack of ability of ciprofloxacin-rifampin prophylaxis to decrease infection-related morbidity in neutropenic patients given cytotoxic therapy and peripheral blood stem cell transplants.

Authors:  M Hidalgo; J Hornedo; C Lumbreras; J M Trigo; C Gómez; S Perea; A Ruiz; R Hitt; H Cortés-Funes
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

2.  In vitro activities of eight macrolide antibiotics and RP-59500 (quinupristin-dalfopristin) against viridans group streptococci isolated from blood of neutropenic cancer patients.

Authors:  F Alcaide; J Carratala; J Liñares; F Gudiol; R Martin
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

3.  Molecular relationships and antimicrobial susceptibilities of viridans group streptococci isolated from blood of neutropenic cancer patients.

Authors:  H Wisplinghoff; R R Reinert; O Cornely; H Seifert
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

4.  A randomized trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis.

Authors:  W V Kern; B Hay; P Kern; R Marre; R Arnold
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

5.  Changing causes of septicaemia in paediatric oncology patients: effect of imipenem use.

Authors:  J W Gray; S J Pedler; A W Craft; J Kernahan; K P Windebank; A D Pearson
Journal:  Eur J Pediatr       Date:  1994-02       Impact factor: 3.183

6.  Antimicrobial activity of cytotoxic drugs may influence isolation of bacteria and fungi from blood cultures.

Authors:  V Peiris; B A Oppenheim
Journal:  J Clin Pathol       Date:  1993-12       Impact factor: 3.411

7.  Defining antibody targets in Streptococcus oralis infection.

Authors:  J P Burnie; W Brooks; M Donohoe; S Hodgetts; A al-Ghamdi; R C Matthews
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

8.  In vitro activities of 22 beta-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood.

Authors:  F Alcaide; J Liñares; R Pallares; J Carratala; M A Benitez; F Gudiol; R Martin
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

9.  Streptococcus mitis strains causing severe clinical disease in cancer patients.

Authors:  Samuel A Shelburne; Pranoti Sahasrabhojane; Miguel Saldana; Hui Yao; Xiaoping Su; Nicola Horstmann; Erika Thompson; Anthony R Flores
Journal:  Emerg Infect Dis       Date:  2014-05       Impact factor: 6.883

10.  Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen.

Authors:  Alaa M Ali; Daniel Weisel; Feng Gao; Geoffrey L Uy; Amanda F Cashen; Meagan A Jacoby; Lukas D Wartman; Armin Ghobadi; Iskra Pusic; Rizwan Romee; Todd A Fehniger; Keith E Stockerl-Goldstein; Ravi Vij; Stephen T Oh; Camille N Abboud; Mark A Schroeder; Peter Westervelt; John F DiPersio; John S Welch
Journal:  Cancer Med       Date:  2017-10-23       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.